
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium is a biotechnology company focused on developing novel therapies for patients with severe autoimmune and inflammatory disorders. The company's lead candidate, EQ504, is a potent and selective AhR modulator that is being developed for targeted local delivery in ulcerative colitis and other gastrointestinal diseases. Equillium's well-funded position and strong management team make it a promising investment opportunity, with potential for significant upside as the company advances its pipeline of innovative treatments.
Bears say
Equillium is a clinical-stage biotechnology company with a focus on developing novel therapies for autoimmune and inflammatory disorders. Their lead therapeutic candidate, EQ504, has shown potential in the treatment of ulcerative colitis and other gastrointestinal diseases. Despite positive pre-clinical data and a promising mechanism of action, risks related to clinical execution, financing, and competition could hinder its success. However, the recent findings highlighting EQ504's potential for deeper and more durable mucosal healing compared to competitors could increase its likelihood of success.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares